Joyti Gore
Los Angeles, CANPI 1225711120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,441, more than ten times the $40 reported in 2023.
Across 94 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$298
- Astellas Pharma US Inc$267
- Merck$211
- Pfizer$193
- Array Biopharma Inc$185
- Johnson & Johnson$166
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,21193%
- Education$1747%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 10 | $298 |
| Astellas Pharma US Inc | 9 | $267 |
| Merck | 8 | $211 |
| Pfizer | 9 | $193 |
| Array Biopharma Inc | 8 | $185 |
| Johnson & Johnson | 6 | $166 |
| Lilly USA, LLC | 6 | $109 |
| Bayer | 4 | $106 |
| Agios Pharmaceuticals, Inc. | 4 | $91 |
| EMD Serono, Inc. | 3 | $89 |
| Legend Biotech USA Inc. | 3 | $89 |
| Karyopharm Therapeutics Inc. | 3 | $81 |
| Pharmaessentia USA Corporation | 2 | $65 |
| Novartis | 4 | $65 |
| AbbVie | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Blueprint Medicines Corporation | 2 | $49 |
| AstraZeneca | 2 | $49 |
| AVEO Pharmaceuticals, Inc. | 2 | $42 |
| Spectrum Pharmaceuticals Inc. | 1 | $39 |
| Genentech USA, Inc. | 1 | $27 |
| Puma Biotechnology, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 43 | $289 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.